Therapeutic Targets for Diabetic Retinopathy A Translational Approach
Auteurs : Li Weiye, Zhang Jingfa
Takes a concise yet comprehensive approach to diabetic eye disorders, covering basic science as well as therapeutic agents with both current and future clinical applications.
Covers current diagnostic and management guidelines as well developments on the horizon that are likely to improve patient outcomes.
Explains the pathophysiological mechanisms of diabetic retinopathy and diabetic macular edema from both a basic and clinical perspective, helping readers seek promising new therapeutic targets.
Consolidates today's available information on this timely topic into a single, convenient resource.
1. Introduction of diabetic retinopathy and principles of treatment
Weiye Li and Jingfa Zhang
2. Diabetes-induced metabolic disorders of diabetic retinopathy
Weiye Li and Jingfa Zhang
3. Diabetic retinopathy, a neurovascular unit disease
Weiye Li and Jingfa Zhang
4. The pathogenic role of apoptosis in the development of diabetic retinopathy
Weiye Li and Jingfa Zhang
5. Diabetic retinopathy, a disease with low-grade inflammation
Weiye Li and Jingfa Zhang
6. Neurodegeneration and microangiopathy in diabetic retina and choroid
Weiye Li and Jingfa Zhang
7. Proliferative diabetic retinopathy, a disease of pathologic angiogenesis and vasculogenesis
Weiye Li and Jingfa Zhang
8. Pathogenesis of diabetic macular edema
Weiye Li and Jingfa Zhang
9. Treatments for diabetic retinopathy and diabetic macular edema in pipeline
Weiye Li and Jingfa Zhang
10. Future perspectives for diabetic retinopathy management
Weiye Li and Jingfa Zhang
Dr. Jingfa Zhang, Senior Scientist and Attending Physician at the Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University, Shanghai, P.R. China, is a physician-scientist focusing on diabetic retinopathy and age-related macular degeneration.
Date de parution : 01-2023
Ouvrage de 322 p.
Thème de Therapeutic Targets for Diabetic Retinopathy :
Mots-clés :
Adaptive immunity; Advanced glycation end products; Angiogenesis; Angiopoietin 2; Angiopoietin-2; Anti-apoptosis; Anti-inflammation; Anti-VEGF; Anti-VEGF therapy; Apoptosis; Artificial intelligence; Astrocytes; Blood-retinal barrier; Blood-retinal barrier breakdown; BRB breakdown; Cell death; Cell therapy; Chemokines; Choriocapillaris; Corticosteroid therapy; Diabetic choroidopathy; Diabetic macular edema; Diabetic retinal microangiopathy; Diabetic retinal neurodegeneration; Diabetic retinal neuronopathy; Diabetic retinopathy; Diabetic vitrectomy; Drainage dysfunction; Endothelial cell; Epidemiology; Gene therapy; Genetics; Glycemic control; Hexosamine biosynthetic pathway; HIF-1a; Hypertension; Inflammation; Inflammtory cytokines; Innate; Integrin; Intracellular edema; Intussusceptive angiogenesis; Laser photocoagulation; Leukocyte adhesion; Leukostasis; Low-grade inflammation; Müller glia; Metabolic memory; Microglia; Microglia activation; Microinflammation; Neuronal dysfunction; Neuroprotection; Neurovascular coupling; Neurovascular unit; Oxidative stress